TNF Pharmaceuticals Secures $7 Million in Private Placement to Advance Innovative Technology

Reuters

Sep 04

TNF Pharmaceuticals Secures $7 Million in Private Placement to Advance Innovative Technology

TNF Pharmaceuticals Inc. (Nasdaq: TNFA) has successfully closed a $7 million private placement financing. The transaction involved the sale of 7,000 shares of convertible preferred stock at $1,000 per share, convertible into 1,400,000 shares of common stock at an initial conversion price of $5.00. The deal was led by the company's largest strategic stockholder with significant participation from existing stockholders. Accompanying the preferred stock are warrants to purchase an additional 1,400,000 shares of common stock at the same conversion price. The funding aims to support TNF's key development milestones, particularly in advancing their innovative light-based computing accelerator for blockchain technology. Executive Chairman Joshua Silverman expressed confidence in the company's value proposition and future strategies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250904261260) on September 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2564377110"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564377110\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564377110?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564377110","market":"us","top_or_hot":-1,"title":"TNF Pharmaceuticals Secures $7 Million in Private Placement to Advance Innovative Technology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TNF Pharmaceuticals Secures $7 Million in Private Placement to Advance Innovative Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TNF Pharmaceuticals Inc. (Nasdaq: TNFA) has successfully closed a $7 million private placement financing. The transaction involved the sale of 7,000 shares of convertible preferred stock at $1,000 per share, convertible into 1,400,000 shares of common stock at an initial conversion price of $5.00. The deal was led by the company's largest strategic stockholder with significant participation from existing stockholders. Accompanying the preferred stock are warrants to purchase an additional 1,400,000 shares of common stock at the same conversion price. The funding aims to support TNF's key development milestones, particularly in advancing their innovative light-based computing accelerator for blockchain technology. Executive Chairman Joshua Silverman expressed confidence in the company's value proposition and future strategies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250904261260) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TNF Pharmaceuticals Secures $7 Million in Private Placement to Advance Innovative Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTNF Pharmaceuticals Secures $7 Million in Private Placement to Advance Innovative Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TNF Pharmaceuticals Secures $7 Million in Private Placement to Advance Innovative Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TNF Pharmaceuticals Inc. (Nasdaq: TNFA) has successfully closed a $7 million private placement financing. The transaction involved the sale of 7,000 shares of convertible preferred stock at $1,000 per share, convertible into 1,400,000 shares of common stock at an initial conversion price of $5.00. The deal was led by the company's largest strategic stockholder with significant participation from existing stockholders. Accompanying the preferred stock are warrants to purchase an additional 1,400,000 shares of common stock at the same conversion price. The funding aims to support TNF's key development milestones, particularly in advancing their innovative light-based computing accelerator for blockchain technology. Executive Chairman Joshua Silverman expressed confidence in the company's value proposition and future strategies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250904261260) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL9hZkcH:1","article_id":"2564377110","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564377110","pubTimestamp":1756991721,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TNF Pharmaceuticals Inc.  has successfully closed a $7 million private placement financing. The transaction involved the sale of 7,000 shares of convertible preferred stock at $1,000 per share, convertible into 1,400,000 shares of common stock at an initial conversion price of $5.00. The deal was led by the company's largest strategic stockholder with significant participation from existing stockholders. Accompanying the preferred stock are warrants to purchase an additional 1,400,000 shares of common stock at the same conversion price. The funding aims to support TNF's key development milestones, particularly in advancing their innovative light-based computing accelerator for blockchain technology. Executive Chairman Joshua Silverman expressed confidence in the company's value proposition and future strategies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药"},"translate_title":"TNF Pharmaceuticals获得700万美元私募以推进创新技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNFA":0.9},"content_text":"TNF Pharmaceuticals Secures $7 Million in Private Placement to Advance Innovative Technology\n    \n\n        TNF Pharmaceuticals Inc. (Nasdaq: TNFA) has successfully closed a $7 million private placement financing. The transaction involved the sale of 7,000 shares of convertible preferred stock at $1,000 per share, convertible into 1,400,000 shares of common stock at an initial conversion price of $5.00. The deal was led by the company's largest strategic stockholder with significant participation from existing stockholders. Accompanying the preferred stock are warrants to purchase an additional 1,400,000 shares of common stock at the same conversion price. The funding aims to support TNF's key development milestones, particularly in advancing their innovative light-based computing accelerator for blockchain technology. Executive Chairman Joshua Silverman expressed confidence in the company's value proposition and future strategies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250904261260) on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}